Bismuth Chemistry Creates More Stable Cell-Penetrating Peptides

Bismuth-cyclized cell-penetrating peptides showed improved cellular entry and metabolic stability compared to linear peptides, avoiding the epimerization problems of previous cyclization methods.

Ritchey, Jeremy L et al.·Molecular pharmaceutics·2024·Preliminary Evidencein vitro
RPEP-09150In vitroPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
In vitro cell culture experiments
Participants
In vitro cell culture experiments

What This Study Found

Bismuth-cyclized cell-penetrating peptides showed improved cellular entry efficiency and metabolic stability compared to linear CPPs, without the epimerization issues of previous cyclization methods.

Key Numbers

Not specified — this is a proof-of-concept study demonstrating the bismuth cyclization method.

How They Did This

Laboratory development and testing of a novel peptide cyclization method using bismuth coordination chemistry.

Why This Research Matters

Getting drugs and research tools inside cells is a major challenge in medicine. Better cell-penetrating peptides could improve drug delivery for many conditions, from cancer to genetic diseases.

The Bigger Picture

Cell-penetrating peptides are a key technology for drug delivery, but linear peptides break down quickly. Better cyclization methods that improve stability without technical drawbacks advance the entire drug delivery field.

What This Study Doesn't Tell Us

This is an early-stage laboratory study. The bismuth-cyclized peptides need to be tested in living organisms to confirm safety and effectiveness.

Questions This Raises

  • ?Is bismuth biocompatible for in vivo use?
  • ?Can this method be applied to therapeutic peptide cargoes?

Trust & Context

Key Stat:
No epimerization Bismuth cyclization avoids the amino acid scrambling (epimerization) that plagued previous peptide cyclization methods
Evidence Grade:
Rated preliminary: proof-of-concept chemistry study demonstrating the method. Biological applications need further validation.
Study Age:
Published in 2024. Novel chemistry approach with potential broad applications in peptide drug delivery.
Original Title:
Bismuth-Cyclized Cell-Penetrating Peptides.
Published In:
Molecular pharmaceutics, 21(10), 5255-5260 (2024)
Database ID:
RPEP-09150

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why cyclize cell-penetrating peptides?

Cyclization makes peptides more rigid, improving their ability to enter cells and resist degradation by enzymes in the body.

What is bismuth cyclization?

A new chemical method using bismuth atoms to create ring-shaped peptides, avoiding technical problems that limited previous cyclization approaches.

Read More on RethinkPeptides

Cite This Study

RPEP-09150·https://rethinkpeptides.com/research/RPEP-09150

APA

Ritchey, Jeremy L; Filippi, Lindsi; Ballard, Davis; Pei, Dehua. (2024). Bismuth-Cyclized Cell-Penetrating Peptides.. Molecular pharmaceutics, 21(10), 5255-5260. https://doi.org/10.1021/acs.molpharmaceut.4c00688

MLA

Ritchey, Jeremy L, et al. "Bismuth-Cyclized Cell-Penetrating Peptides.." Molecular pharmaceutics, 2024. https://doi.org/10.1021/acs.molpharmaceut.4c00688

RethinkPeptides

RethinkPeptides Research Database. "Bismuth-Cyclized Cell-Penetrating Peptides." RPEP-09150. Retrieved from https://rethinkpeptides.com/research/ritchey-2024-bismuthcyclized-cellpenetrating-peptides

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.